Global Data Reports

Approval of KYNAMRO (mipomersen, apoB synthesis inhibitor, homozygous – HoFH; PhIII for heterozygous familial hypercholesterolemia –HeFH, partnered with Sanofi) in US and discounted pricing has removed the overhang of uncertainty.  Upside from the New Orphan Indications with Global Partners (GSK, BIIB, AZN in 2012) and maturing pipeline remains. Successful systemic…

Approval of KYNAMRO (mipomersen, apoB synthesis inhibitor, homozygous – HoFH; PhIII for heterozygous familial hypercholesterolemia –HeFH, partnered with Sanofi) in US and discounted pricing has removed the overhang of uncertainty.  Upside from the New Orphan Indications with Global Partners (GSK, BIIB, AZN in 2012) and maturing pipeline remains. Successful systemic…

Approval of KYNAMRO (mipomersen, apoB synthesis inhibitor, homozygous – HoFH; PhIII for heterozygous familial hypercholesterolemia –HeFH, partnered with Sanofi) in US and discounted pricing has removed the overhang of uncertainty.  Upside from the New Orphan Indications with Global Partners (GSK, BIIB, AZN in 2012) and maturing pipeline remains. Successful systemic…

Approval of KYNAMRO (mipomersen, apoB synthesis inhibitor, homozygous – HoFH; PhIII for heterozygous familial hypercholesterolemia –HeFH, partnered with Sanofi) in US and discounted pricing has removed the overhang of uncertainty.  Upside from the New Orphan Indications with Global Partners (GSK, BIIB, AZN in 2012) and maturing pipeline remains. Successful systemic…

Approval of KYNAMRO (mipomersen, apoB synthesis inhibitor, homozygous – HoFH; PhIII for heterozygous familial hypercholesterolemia –HeFH, partnered with Sanofi) in US and discounted pricing has removed the overhang of uncertainty.  Upside from the New Orphan Indications with Global Partners (GSK, BIIB, AZN in 2012) and maturing pipeline remains. Successful systemic…

Approval of KYNAMRO (mipomersen, apoB synthesis inhibitor, homozygous – HoFH; PhIII for heterozygous familial hypercholesterolemia –HeFH, partnered with Sanofi) in US and discounted pricing has removed the overhang of uncertainty.  Upside from the New Orphan Indications with Global Partners (GSK, BIIB, AZN in 2012) and maturing pipeline remains. Successful systemic…

Approval of KYNAMRO (mipomersen, apoB synthesis inhibitor, homozygous – HoFH; PhIII for heterozygous familial hypercholesterolemia –HeFH, partnered with Sanofi) in US and discounted pricing has removed the overhang of uncertainty.  Upside from the New Orphan Indications with Global Partners (GSK, BIIB, AZN in 2012) and maturing pipeline remains. Successful systemic…

Approval of KYNAMRO (mipomersen, apoB synthesis inhibitor, homozygous – HoFH; PhIII for heterozygous familial hypercholesterolemia –HeFH, partnered with Sanofi) in US and discounted pricing has removed the overhang of uncertainty.  Upside from the New Orphan Indications with Global Partners (GSK, BIIB, AZN in 2012) and maturing pipeline remains. Successful systemic…

> Approval of KYNAMRO (mipomersen, apoB synthesis inhibitor, homozygous – HoFH; PhIII for heterozygous familial hypercholesterolemia –HeFH, partnered with Sanofi) in US and discounted pricing has removed the overhang of uncertainty.  Upside from the New Orphan Indications with Global Partners (GSK, BIIB, AZN in 2012) and maturing pipeline remains. Successful…

Approval of KYNAMRO (mipomersen, apoB synthesis inhibitor, homozygous – HoFH; PhIII for heterozygous familial hypercholesterolemia –HeFH, partnered with Sanofi) in US and discounted pricing has removed the overhang of uncertainty.  Upside from the New Orphan Indications with Global Partners (GSK, BIIB, AZN in 2012) and maturing pipeline remains. Successful systemic…